Azenosertib + Gemcitabine
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteosarcoma
Conditions
Osteosarcoma
Trial Timeline
Aug 1, 2021 → Mar 30, 2024
NCT ID
NCT04833582About Azenosertib + Gemcitabine
Azenosertib + Gemcitabine is a phase 1/2 stage product being developed by Zentalis Pharmaceuticals for Osteosarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04833582. Target conditions include Osteosarcoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04833582 | Phase 1/2 | Completed |
Competing Products
18 competing products in Osteosarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lenvatinib + Ifosfamide + Etoposide + Lenvatinib | Eisai | Phase 2 | 52 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| pemetrexed | Eli Lilly | Phase 2 | 52 |
| Camrelizumab in Combination With Neoadjuvant Chemotherapy | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Olaparib + Ceralasertib | AstraZeneca | Phase 2 | 52 |
| Saracatinib + Placebo | AstraZeneca | Phase 2 | 52 |
| robatumumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| pazopanib | Novartis | Phase 2 | 52 |
| Avelumab | Pfizer | Phase 2 | 51 |
| Nivolumab + Azacitidine | Bristol Myers Squibb | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cisplatin liposomal | Insmed | Phase 1/2 | 38 |
| Cabozantinib | Ipsen | Phase 2 | 49 |
| Sm-EDTMP | Jazz Pharmaceuticals | Phase 2 | 49 |
| LNTH2403 Phase 1 dose + Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). | Lantheus Holdings | Phase 1/2 | 38 |
| REOLYSIN® | Oncolytics Biotech | Phase 2 | 44 |